---

PTSD, Complex PTSD, Grief, Bereavement & End-of-Life Psychiatric Disorders

A Comprehensive Clinical Reference

---

PART I: POST-TRAUMATIC STRESS DISORDER (PTSD)

1. Historical Context

---

2. DSM-5-TR Diagnostic Criteria for PTSD

• Direct experience
• Witnessing the event in person
• Learning it occurred to a close friend/family member
• Repeated or extreme indirect exposure in occupational context (e.g., first responders)

1. Recurrent involuntary distressing memories
2. Recurrent distressing dreams
3. Dissociative reactions (flashbacks) — re-experiencing the event as if happening now
4. Intense or prolonged psychological distress at trauma cues
5. Marked physiologic reactions to internal/external trauma cues

1. Avoidance of distressing memories, thoughts, or feelings
2. Avoidance of external reminders (people, places, activities, objects)

1. Inability to remember an important aspect of the event (dissociative amnesia)
2. Persistent exaggerated negative beliefs ("I am bad," "No one can be trusted")
3. Persistent distorted cognitions about cause/consequences → self-blame or blaming others
4. Persistent negative emotional state (fear, horror, anger, guilt, shame)
5. Markedly diminished interest in significant activities
6. Feelings of detachment or estrangement from others
7. Persistent inability to experience positive emotions (emotional numbing/anhedonia)

1. Irritable behavior and angry outbursts (verbal or physical aggression)
2. Reckless or self-destructive behavior
3. Hypervigilance
4. Exaggerated startle response
5. Concentration problems
6. Sleep disturbance

• With dissociative symptoms: Depersonalization (detachment from one's mental processes/body) or Derealization (unreality of surroundings)
• With delayed expression: Full criteria not met until ≥6 months post-event

---

3. ICD-11 PTSD Criteria (for comparison)

1. Re-experiencing in the here and now (intrusive memories, flashbacks, nightmares that feel present-day vivid)
2. Avoidance of trauma-related thoughts/reminders
3. Heightened sense of current threat (hypervigilance, exaggerated startle)

---

4. Neurobiology of PTSD

• Memory consolidation/reconsolidation: Aversive memories are over-consolidated, with defective extinction
• Amygdala: Hyperactivated; drives hypervigilance, exaggerated threat detection
• Prefrontal cortex (medial): Hypoactivated; fails to inhibit amygdala fear responses
• Hippocampus: Reduced volume (stress-related glucocorticoid toxicity); impairs contextual memory discrimination (confusing past trauma with present safety)
• HPA axis dysregulation: Paradoxically low basal cortisol with hypersensitive negative feedback (unlike MDD which has elevated cortisol)
• Noradrenergic hyperactivity: Drives hyperarousal, startle, nightmares (explains prazosin efficacy)
• Inflammatory markers: Elevated IL-6, CRP, and TNF-α in chronic PTSD
• Core conceptualization: PTSD is a "disorder of recovery" — acute stress responses fail to resolve; fear extinction is impaired; safety signals go unprocessed

---

5. Epidemiology and Risk Factors

• Lifetime prevalence: ~7–8% in the general U.S. population
• Up to 30% of trauma-exposed individuals develop PTSD
• Higher in combat veterans, sexual assault survivors, disaster survivors

• Prior psychiatric history or trauma history
• Female sex (2× risk vs. males)
• Dissociation at the time of trauma (peritraumatic dissociation)
• Lack of social support
• Severity of trauma (prolonged, intentional/interpersonal > accidental)
• Genetic predisposition (serotonin transporter polymorphisms, FKBP5)
• Pre-existing anxiety or depression

• Major depressive disorder (MDD): co-occurs in >40% at any time, 95% lifetime
• Alcohol and substance use disorders (AUD in particular; bidirectional risk)
• Anxiety disorders, panic disorder
• Chronic pain, somatic disorders
• Suicidality significantly elevated

---

6. PTSD Treatment

First-Line Psychotherapies (Strong Evidence)

Pharmacotherapy

• MDMA-assisted psychotherapy (midomafetamine + CBT): Phase 3 trials show superiority over CBT alone; mechanism involves oxytocin-like increased empathy, reduced threat processing — facilitates trauma processing. Note: MDMA alone has no known PTSD efficacy; requires structured psychotherapy context
• Stellate ganglion block: Sympathetic nerve block; promising pilot data
• Ketamine: NMDA antagonist; rapid-acting; RCTs ongoing
• Transcranial Magnetic Stimulation (TMS): Targeting right DLPFC

---

7. Prognosis for PTSD

• ~33–50% recover without treatment within 3–6 months
• Chronic PTSD (>12 months): ~30% remain chronically ill without treatment
• With evidence-based treatment: significant response in 60–80%; remission in 30–40%
• Predictors of poor prognosis: Ongoing trauma/unsafe environment, severe initial symptoms, peritraumatic dissociation, comorbid SUD, lack of social support, medical illness
• Predictors of good prognosis: Acute onset (<6 months), adequate social support, no comorbid substance use, early treatment engagement

---

---

PART II: COMPLEX PTSD (C-PTSD)

1. History and Conceptual Origins

---

2. ICD-11 Criteria for Complex PTSD

---

3. Differentiating PTSD from C-PTSD

---

4. Differential Diagnosis of C-PTSD

---

5. Assessment Tools

• International Trauma Questionnaire (ITQ): Gold standard for ICD-11 PTSD and C-PTSD; validated, widely used
• PCL-5 (PTSD Checklist for DSM-5): 20 items; used for DSM-5 PTSD severity
• CAPS-5 (Clinician-Administered PTSD Scale): Gold standard for DSM-5 PTSD structured clinical interview
• Structured Clinical Interview for DSM-5 (SCID-5): Differential diagnosis
• Full differential includes: MDD, BPD, DID, SUD, ADHD screening

---

6. Treatment of C-PTSD

Phase-Based Treatment Model (Current Best Practice)

• Build therapeutic alliance
• Establish physical/emotional safety
• Teach affect regulation, distress tolerance, and grounding skills
• STAIR (Skills Training in Affective and Interpersonal Regulation): 4-module structured skills program targeting each ICD-11 C-PTSD domain; originally for sexual abuse survivors; now tested more broadly — shows positive results vs. treatment-as-usual

• Trauma-focused narrative work (e.g., STAIR + Narrative Story Telling, EMDR, PE, CPT)
• Multi-component approaches outperform single-component when sequenced properly: DBT-PTSD (combining DBT skills + trauma exposure) and STAIR + narrative therapy both show positive results in RCTs

• Identity reconstruction; rebuilding relationships; integrating trauma into a coherent life narrative

• A 2026 systematic review and meta-analysis (PMID 41949043, Eur J Psychotraumatol) found that phase-based vs. non-phase-based interventions for C-PTSD both show benefit; the advantage of phase-based treatment is present but the field requires more RCTs
• People with C-PTSD can also benefit from standard PTSD treatments (PE, EMDR, CPT); they do not need to be excluded from these — but higher dropout rates suggest stabilization skills first may improve retention and outcomes

Pharmacotherapy for C-PTSD

• Same principles as PTSD: SSRIs first line (sertraline, paroxetine)
• Add prazosin for nightmares/hyperarousal
• Mood stabilizers (lamotrigine, valproate) may help severe affect dysregulation
• Low-dose antipsychotics (e.g., risperidone, quetiapine) cautiously for dissociation, hyperarousal, or psychotic-like symptoms
• Avoid: Benzodiazepines (risk of dependence, worsen affect regulation and processing)

---

7. Prognosis for C-PTSD

• Longer course and greater treatment burden than PTSD
• Good outcomes are achievable with structured, phased treatment
• Higher attrition rates from therapy — therapeutic alliance, safety, and stabilization skills first are critical
• Comorbid BPD, SUD, severe dissociation → poorer prognosis
• Social support and absence of ongoing trauma are the strongest protective factors

---

---

PART III: GRIEF, BEREAVEMENT, AND MOURNING

1. Definitions

---

2. Normal Bereavement Reactions

1. Protest — initial shock, searching behavior; disbelief; searching for the lost person
2. Despair — as hope of reunion fades; yearning, sadness, withdrawal
3. Detachment/Disorganization — withdrawal from the lost attachment
4. Reorganization — gradual adaptation; forming new attachments while maintaining symbolic connection to the deceased

• Sadness, weeping, yearning
• Insomnia, appetite disturbance
• Transient auditory/visual experiences of the deceased (normal; not psychosis)
• Social withdrawal
• Difficulty concentrating
• Anniversary reactions (acute grief rekindled on holidays, birthdays, or the death anniversary)

---

3. Kübler-Ross Stages of Dying/Grief (1969)

---

4. Anticipatory Grief

• Grief reactions triggered by the slow dying process of a loved one
• May soften the eventual blow — but can also lead to premature separation and emotional withdrawal from the dying person
• May actually intensify the ultimate loss if the period heightened intimacy
• Clinically important: family may disengage from the dying patient before death, which can leave both parties isolated

---

5. Types and Variations of Bereavement

---

6. Anniversary Reactions

---

---

PART IV: PATHOLOGICAL GRIEF — PROLONGED GRIEF DISORDER (PGD)

1. Definition and Diagnostic Criteria (DSM-5-TR; ICD-11)

• Death of someone close ≥12 months ago (or ≥6 months in children)
• Intense yearning/longing for the deceased AND preoccupation with the deceased (or circumstances of death) — present most days at an intense level
• Plus ≥3 of:
  • Identity disruption ("part of myself has died")
  • Marked disbelief about the death
  • Avoidance of reminders of the death (or the opposite — intense preoccupation)
  • Intense emotional pain (anger, bitterness, sorrow)
  • Difficulty engaging with others or pursuing interests
  • Emotional numbness
  • Feeling that life is meaningless
  • Intense loneliness
• Causes clinically significant distress or functional impairment
• Not better explained by MDD, PTSD, or normal cultural bereavement

---

2. Differentiating Normal Grief vs. PGD vs. MDD vs. PTSD

---

3. Risk Factors for PGD

• Sudden, unexpected death (homicide, suicide, accidents)
• Death of a child
• Traumatic circumstances of death (witnessing, violent death)
• Ambivalent or highly dependent relationship with deceased
• Prior trauma or grief experiences
• Social isolation; lack of support
• Pre-existing anxiety, depression, or attachment insecurity

---

4. Treatment of Prolonged Grief Disorder

First-Line: Grief-Focused Psychotherapy

• Evidence-based, grief-specific; adapted from CBT + IPT framework
• Components: grief monitoring diary, telling the story of the death, revisiting the moment of loss, engagement exercises (re-engaging with life), imaginal conversations with the deceased
• Superior to standard IPT for PGD in RCTs

• Multiple RCTs and meta-analyses (PMID 38573714, J Consult Clin Psychol 2024) confirm efficacy
• Targets avoidance of grief, maladaptive cognitions about the loss, re-engagement with life
• A 2024 network meta-analysis (PMID 38970900) found grief-focused CBT and CGT had the strongest evidence among psychotherapies for PGD

• Mindfulness-Based Interventions: Systematic review (PMID 41382319, 2025) shows mindfulness aids adaptation to bereavement, especially reducing avoidance and rumination
• IPT (Interpersonal Therapy): Useful when grief is complicated by interpersonal transitions
• Group therapy / bereavement support groups: Particularly for widows/widowers; ~30% report isolation; self-help groups restore social functioning
• Online/digital CBT: Accessible; emerging evidence base

Pharmacotherapy for PGD

• Citalopram/SSRIs: Some evidence but less robust than for MDD; may help comorbid depression
• Bupropion: Some evidence for grief-related depression
• Benzodiazepines are contraindicated — interfere with grief processing; risk dependence
• Pharmacotherapy alone is insufficient; always combine with psychotherapy

---

5. Grief Therapy Principles (General)

1. Bereaved persons in normal grief should not routinely be referred to psychiatry — grief is not a disorder
2. Mild sedation for acute insomnia is acceptable; antidepressants and anxiolytics are rarely indicated in normal grief
3. The mourning process — however painful — must be experienced for successful resolution; "narcotizing" patients with drugs interferes with healthy processing
4. Individual therapy: Encourage expression of loss feelings, including ambivalent/angry feelings toward the deceased (normalize these)
5. Group therapy is highly effective — counters isolation; provides mutual validation
6. Regularly scheduled sessions allow gradual emotional engagement with loss

---

---

PART V: END-OF-LIFE PSYCHIATRIC ISSUES

1. Psychological Stages in the Dying Patient (Kübler-Ross)

• No patient follows a rigid sequence — never say "they should be in anger by now"
• A patient stuck in denial throughout may be protective — do not forcibly move them
• Anger is often displaced onto clinicians — do not take it personally; this is adaptive
• Depression in terminal illness is different from MDD — it may be a normal preparatory grief; assess carefully before treating aggressively with antidepressants

---

2. Depression vs. Sadness vs. Adjustment Disorder at End of Life

---

3. Demoralization Syndrome

• Core features: Loss of meaning, existential despair, hopelessness, helplessness, sense of entrapment
• Key distinction from MDD: Capacity for pleasure in the moment is preserved; can experience joy transiently, but overwhelmed by suffering and meaninglessness when alone
• Treatment: Meaning-Centered Psychotherapy (MCP) (Breitbart et al.) — draws on Frankl's logotherapy; helps patients find meaning in suffering; shown effective in RCTs in advanced cancer populations

---

4. Anxiety at End of Life

• Fear of the dying process (pain, suffocation, loss of control)
• Fear of abandonment and dying alone
• Unfinished business (interpersonal, financial, spiritual)
• Existential fears (afterlife, legacy, meaninglessness)
• Medical causes: hypoxia, delirium, uncontrolled pain, metabolic disturbances

• Benzodiazepines (lorazepam, clonazepam) are appropriate at end of life for anxiety and terminal agitation (unlike in grief therapy above)
• SSRIs for sustained anxiety
• Antipsychotics for delirium-associated agitation
• Non-pharmacologic: presence, life review, pastoral care, music therapy, relaxation

---

5. Delirium at End of Life

• Highly prevalent (up to 85% in final days)
• Terminal agitation/terminal restlessness — most distressing to family; requires active management
• Management: Haloperidol (first-line), olanzapine, lorazepam adjunctively; palliative sedation in refractory cases
• Family education critical — delirium may cause the patient to appear fearful or say distressing things

---

6. Communication at End of Life

• Schedule sufficient time; private space; patient clothed (on equal footing with physician)
• Spouse/partner present if patient desires
• Use clear, simple language; do not assume education level aligns with health literacy
• Information may need repetition across multiple visits
• Do not give precise prognoses (survival time estimates are typically inaccurate and cause harm if wrong) — frame with uncertainty and ranges
• Make explicit that you will be with them through the entire illness
• Never criticize a patient's emotional response; never take anger personally

• 80–90% of patients with malignancies want to know their diagnosis — standard is honest, compassionate disclosure
• Some patients explicitly request not to know — honor this, but inform a close family member
• Informed consent is legally required in the U.S. for treatment decisions — patients must receive adequate information about diagnosis, prognosis, and options

---

7. Advance Directives and End-of-Life Decision Making

• Advance directive / living will: Documents patient's wishes for life-sustaining treatment when they can no longer speak for themselves
• Healthcare proxy / durable power of attorney for healthcare: Designates a surrogate decision-maker
• DNR (Do Not Resuscitate) / DNI orders: Physician orders based on patient/surrogate discussion
• Psychiatric consultation is valuable when decisional capacity is in question (depression, delirium, cognitive impairment)
• The ethical frameworks: autonomy, beneficence, non-maleficence, justice

---

8. Physician-Assisted Death (Medical Aid in Dying)

• Terminal illness with ≤6 months prognosis
• Decision-making capacity
• Repeated voluntary requests
• Evaluation by ≥2 physicians
• Psychiatric consultation required if underlying depression or decisional impairment suspected — this is a critical safeguard

---

---

PART VI: RELATED CONDITIONS — QUICK REFERENCE

Acute Stress Disorder (ASD)

• Same trauma exposure as PTSD
• Duration: 3 days to 1 month post-trauma
• Symptoms: intrusions, avoidance, negative mood, dissociation, hyperarousal
• Role of ASD: ~50% of those with ASD develop PTSD; most who develop PTSD had prior ASD
• Treatment: Early trauma-focused CBT; EMDR; brief interventions
• Do NOT use psychological debriefing (CISD) as universal post-trauma intervention — evidence shows it does not prevent PTSD and may worsen outcomes in some

Adjustment Disorder

• Emotional/behavioral symptoms in response to an identifiable stressor
• Onset within 3 months of stressor; resolve within 6 months of stressor removal
• Subtypes: depressed mood, anxious, mixed anxiety-depressed, disturbance of conduct, mixed
• Does not meet criteria for another mental disorder (PTSD, MDD)
• Treatment: Brief psychotherapy; stress management; short-term pharmacotherapy rarely needed

Reactive Attachment Disorder / Disinhibited Social Engagement Disorder

• Children exposed to severe neglect or inadequate caregiving
• Relevant in pediatric end-of-life: children losing primary caregiver (parent death) at early age

Complicated Bereavement in Special Populations

---

---

PART VII: CLINICAL DIFFERENTIATION SUMMARY TABLE

---

PART VIII: PROGNOSIS OVERVIEW

---

Key Clinical Pearls

1. PTSD ≠ C-PTSD: Both are real; C-PTSD is ICD-11 only (not DSM-5); requires PTSD + all 3 DSO domains. DSM-5 clinicians use PTSD + BPD/MDD comorbidities to capture similar clinical complexity.
2. Normal grief is not a disorder — resist pathologizing it. Do not prescribe antidepressants for acute normal bereavement; this inhibits healthy processing.
3. PGD is a disorder when yearning and preoccupation persist for >12 months with functional impairment. First-line is grief-specific psychotherapy (PGT/CGT), not standard CBT for depression.
4. At end of life, depression and demoralization are not the same. Demoralization (loss of meaning, preserved pleasure capacity) responds to meaning-centered therapy; MDD responds to antidepressants.
5. Benzodiazepines are contraindicated in grief, PTSD, and C-PTSD for therapeutic use — but are appropriate for acute end-of-life symptom management (terminal agitation, anxiety, dyspnea).
6. Anniversary reactions are normal and may be confused with relapse of PTSD or PGD — key distinction is their temporal pattern and brief, self-limited nature.
7. MDMA-assisted psychotherapy shows promise in treatment-resistant PTSD but requires structured psychotherapy context; FDA review ongoing (MDMA alone has no PTSD efficacy).
8. Suicidal ideation must always be assessed in PTSD, C-PTSD, PGD, and end-of-life demoralization — risk is significantly elevated in all.

---

• Kaplan & Sadock's Synopsis of Psychiatry (Ch. 29.1 — Death, Dying, Bereavement)
• Kaplan & Sadock's Comprehensive Textbook of Psychiatry (Ch. PTSD — DSM-5 criteria, neurobiology, treatment)
• Goodman & Gilman's Pharmacological Basis of Therapeutics (PTSD pharmacotherapy)
• VA PTSD Clinical Resource Center — Complex PTSD Assessment & Treatment (2025)
• PMC Review: "PTSD and complex PTSD, current treatments and debates" (2025) [PMC12466117]
• BMJ Clinical Review: "Diagnosis and management of complex PTSD" (2024)
• PMID 41949043 — Phase-based vs. non-phase-based for C-PTSD (Meta-analysis, Eur J Psychotraumatol 2026)
• PMID 38573714 — Grief-focused CBT for PGD (Meta-analysis, J Consult Clin Psychol 2024)
• PMID 38970900 — Psychotherapies for PGD: network meta-analysis (Asian J Psychiatr 2024)
• PMID 40180039 — Psychotherapy for PGD systematic review (J Affect Disord 2025)
• PMID 41382319 — Mindfulness in bereavement adaptation (Clin Psychol Psychother 2025)